Tinengotinib
From Wikipedia, the free encyclopedia
Chemical compound
This article is an orphan, as no other articles introduce links to this page from related articles ; try the Find link tool for suggestions. (November 2024)
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | TT-00420 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H19ClN6O |
| Molar mass | 394.86 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tinengotinib is an investigational new drug that is being evaluated for the treatment of cancer.[1]
It is an multi-kinase inhibitor designed to target a range of kinases involved in cancer cell proliferation, angiogenesis, and immune response modulation. Specifically, it inhibits fibroblast growth factor receptors (FGFRs) 1–3, janus kinase (JAK) 1/2, vascular endothelial growth factor receptors (VEGFRs), and aurora kinases A/B.[2]
References
[edit ]- ^ "Tinengotinib - TransThera Biosciences". AdisInsigh. Springer Nature Switzerland AG.
- ^ Peng P, Qiang X, Li G, Li L, Ni S, Yu Q, et al. (February 2023). "Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer". Molecular Cancer Therapeutics. 22 (2): 205–214. doi:10.1158/1535-7163.MCT-22-0012. PMC 9890131 . PMID 36223547.
Stub icon
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.